Medication management for older World Trade Center responders
Promoting Healthy Aging Among WTC Responders: Frailty Trajectories And Intervention Strategies
This project will try an educational brochure for WTC responders aged 50+ who take certain medicines to prompt conversations with their doctors about safely stopping unnecessary drugs.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 50 (estimated) |
| Ages | 50 Years and up |
| Sex | All |
| Sponsor | Icahn School of Medicine at Mount Sinai Academic / other |
| Locations | 1 site (New York, New York) |
| Trial ID | NCT07022990 on ClinicalTrials.gov |
What this trial studies
Participants are WTC responders aged 50 and older enrolled in an existing cohort who take at least one of five medication classes linked to harms in older adults (proton pump inhibitors, benzodiazepines/Z‑drugs, first‑generation antihistamines, or skeletal muscle relaxants). Participants complete baseline surveys about beliefs and attitudes toward medications and deprescribing, receive a patient education brochure about one of the medication classes they take, and are encouraged to discuss deprescribing options with their prescribing clinician. The study team will track whether these brochures trigger physician–patient conversations and collect follow-up survey data on acceptance of deprescribing and any perceived effects on the clinician–patient relationship. Any medication changes would occur only under the guidance of the participant's prescriber and the intervention is delivered at Mount Sinai in New York.
Who should consider this trial
Good fit: Ideal participants are WTC responders aged 50 or older who are enrolled in the parent Mount Sinai cohort and currently take at least one medication in the listed classes (PPIs, benzodiazepines/Z‑drugs, first‑generation antihistamines, or skeletal muscle relaxants).
Not a fit: Patients not taking any of the listed medication classes, not enrolled in the parent cohort, or whose prescribers are unwilling to consider deprescribing are unlikely to benefit.
Why it matters
Potential benefit: If successful, this could reduce unnecessary medications and medication-related harms among aging WTC responders.
How similar studies have performed: Previous deprescribing efforts using patient education and clinician engagement have shown mixed but encouraging results in reducing potentially inappropriate medications, so this approach has some supportive evidence though it is not universally proven.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria:
* A WTC responder already enrolled in the "Promoting Healthy Aging Among WTC Responders: Frailty Trajectories and Intervention Strategies" study cohort
* aged 50 years or older, and
* taking one of the five medication classes:
* proton pump inhibitors (PPIs),
* benzodiazepine (BZs) and
* non-benzodiazepine sedative hypnotics ("Z-drugs"),
* first-generation antihistamines (FGA), and
* skeletal muscle relaxants (SMR).
Exclusion Criteria:
* None
Where this trial is running
New York, New York
- Icahn School of Medicine at Mount Sinai — New York, New York, United States (Recruiting)
Study contacts
- Principal investigator: Fred Ko, MD — Icahn School of Medicine at Mount Sinai
- Study coordinator: Patricia Kim
- Email: patricia.kim@mssm.edu
- Phone: 212-241-9370
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.